Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Innate Pharma Shares Efficacy And Safety Phase 1 /2 Results Of NK Cell Engager SAR443579 / IPH6101 Developed By Sanofi At ASH 2023

Author: Benzinga Newsdesk | December 11, 2023 04:19am
  • SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi
  • SAR443579 induced clinical benefit in patients with R/R AML with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, and was well tolerated up to doses of 6 mg/kg
  • SAR443579 demonstrated durable responses with two responders remaining in remission beyond 8.8 and 12.2 months of treatment

Posted In: IPHA SNY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist